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a b s t r a c t
Resveratrol, a polyphenol derived e.g. from red grapes, has been shown to mediate several positive bio-
logical actions such as protection of cells against oxidative stress. It can also influence cell signaling, but
the mechanisms behind its antioxidant properties are largely unknown. Here we show that RSV reduces
oxidative stress and enhances cell survival in PC6.3 cells depending on the concentration. In these cells,
RSV increased the levels of antioxidants, SOD2 and TRX2, and of X chromosome-linked inhibitor of apop-
tosis protein. RSV also activated NFkB signaling as shown using luciferase reporter constructs. These
findings show that RSV regulates oxidative stress and mitochondrial antioxidants in neuronal cells. This
may contribute to cell protection in various brain disorders.
© 2010 Elsevier Ireland Ltd. All rights reserved.
Resveratrol (3,4′,5-trihydroxystilbene; RSV) is a polyphenol com-
pound primarily found in grapes and red wine. RSV has a large
number of biological actions including protection of cells against
oxidative stress [6]. The capability of RSV to protect against
ischemic brain damage has been reported, and RSV could be a
useful compound in the treatment of neurodegenerative diseases
like Huntington’s, Parkinson’s and Alzheimer’s disease as well
[2,7–9,19,20,25].
Mechanisms behind antioxidant properties of RSV are not
fully understood but it has been reported that it affects to acti-
vation of certain genes and proteins: it increases the activity
of AMP-activated kinase (AMPK), Silent Information Regulator 1
(SIRT-1), and peroxisome proliferator-activated receptor gamma
co-activator 1 alpha (PGC-1a) [5,17]. PGC-1a in turn has shown to
be co-induced with several intracellular antioxidant enzymes [24].
RSV is also able to affect survival pathways like NFkB and mitogen
activated protein kinases (MAPKs) [1,11,16]. However as shown
previously the biological outcome of RSV treatments may depend
on the cell type and the concentration of the compound used. Thus
higher concentrations of RSV have been shown to trigger apoptosis
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instead of survival in tumor cell and in cultured endothelial cells
[12,13]. In this work we have studied this in more detail and inves-
tigated the connection between RSV and oxidative stress in PC6.3
cells that is a neuron-like cell line from the peripheral nervous sys-
tem. Data showed that RSV at lower concentrations had a beneficial
effect in PC6.3 cells, counteracting oxidative stress and increasing
cell viability. Treatmentwith RSV increased levels ofmitochondrial
antioxidants and activated NFkB signaling that may contribute to
cell protection.
Neuron-like PC6.3 cells were cultured in RPMI 1640 medium,
containing 2mM Glutamax with 10% Horse Serum (HS) and 5%
Fetal Calf Serum (FCS). Approximately 30×103 cells per well in
collagen-coated 96-well dish (Costar) plates were stimulated with
50mM xanthine (X; Sigma) and 50mU/ml xanthine oxidase (XO;
Sigma) for 24h in 1% FCS to induce oxidative stress in the pres-
ence and absence of 30min pretreatment with 50 and 75mM RSV.
Cell viabilitywasdeterminedbyMTTassay. Briefly, 0.5mg/mlMTT-
solution (Thiazolyl Blue TetrazoliumBromide, Sigma)was added to
the cells for the last 2h (+37 ◦C). Then medium was removed and
isopropanol-/HCl-solution was added. The dye formed was mea-
sured at 560nm, and the absorbance was linear to the number of
viable cells.
PC6.3-cells in 6 cm plates (Nunc) were stimulated with 100mM
X and 200mU/ml XO for 3h in the presence and absence of
30min pretreatmentwith 50 and 75mMRSV. 10mMdihydroethid-
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ium (DHE; Molecular Probes) was added for the last 15min, and
then cells were suspended into PBS and immediately examined
by fluorescent activated cell sorter (FACS) Aria (BD Biosciences).
DHE-positive cells were calculated with excitation at 488nm and
emission at 595nm.
Total RNA was extracted from control and treated PC6.3-cells.
PCRwas carried out as described previously [15]. To quantify SOD2,
TRX2 and XIAP levels, we analyzed the cDNA samples by using the
followingprimers: XIAP: FW5′-TGCTGGACTCTACTACA-3′ andRV
5′-GAC TTG ACT CAT CCT GCGA-3′; SOD2: FW5′-GCC TGC ACT GAA
GTT CAA TG-3′ and RV 5′-ATC TGT AAG CGA CCT TGC TC-3′; TRX2:
FW 5′-GGA CTT TCA TGC ACA GTG-3′ and RV 5′-CGT CCC CGT TCT
TGA T-3′.b-Actin from same cDNA sampleswas used to control the
total cDNA levels with the following primers: FW 5′-CAC ACT GTG
CCC ATC TAT GA-3′ and RV 5′-CCA TCT CTT GCT CGA AGT CT-3′.
Cells were lysed in a buffer containing 50mM Tris–HCl
(pH 7.4), 1% NP-40, 0.25% natriumdeoxycholate, 150mM NaCl,
1mM EDTA and protease inhibitors (Roche). Protein concen-
tration was determined by BC Assay: protein quantitation kit
(Uptima, Interchim). 20–40mg proteins were separated using
SDS-PAGE gels by electrophoresis and transferred to a nitrocel-
lulose membrane (Hybond-C Extra, Amersham Biosciences UK
Limited), blocked for 1h in room temperature in Tris-buffered
saline (TBS) and 5% skim milk, and incubated overnight at +4 ◦C
with primary antibodies diluted blocking buffer. Used antibod-
ies were against SOD2 (AbFrontier) 1:15,000, TRX2 (AbFrontier)
1:1000 or XIAP (BD Transduction Laboratories) 1:5000. Anti-actin
(Sigma) 1:1000 was used as a loading control. Next day mem-
brane was incubated with horseradish peroxidase conjugated
secondaryantibodies (1:2500, Pierce) for1handdetectionwasper-
formed using SuperSignal®West Pico Chemiluminescent Substrate
(Pierce). Quantifications were performed using ImageJ.
PC6.3-cells in 6-well plates (3.5 cm) were transfected with
0.5mg NFkB Luciferase Reporter and 0.01mg Renilla luciferase pRL-
TK control plasmid. Cells were stimulated with 50mM and 75mM
RSV for 24 and 48h. Then cells were lysed in Passive lysis buffer
(Promega). For assay the expression of both Renilla and firefly
luciferase,we used the dual luciferase substrate (Promega), and the
activitiesweremeasuredby luminometer (TD-20/20, Luminometer
Turner Designs). The values for firefly luciferase were normalized
to the Renilla luciferase activity.
One-way ANOVA with pots hoc-tests was used for statistical
comparisons of our experiments.
Based on the perceived antioxidant properties of RSV, we first
investigated the capability of RSV pretreatment to reduce oxidative
stress in our system. Neuron-like PC6.3-cells were pretreated with
50 or 75mM RSV, and after 30min were stimulated with 100mM
xanthine and 200mU/ml xanthine oxidase for 3h. 10mMDHEwas
added for the last 15min, and the DHE-positive cell number was
calculated by FACSAria and expressed as relative number of con-
trol. The data showed that both 50mM and 75mM RSV reduce the
generation of intracellular ROS both in control cells and after expo-
sure to oxidative stress by X+XO (Fig. 1a). The effect was about the
same with both RSV concentrations.
We also examined cell viability with MTT assay following 24h
X+XO (50mM+50mU/ml) treatment, and found out that both RSV
concentrations (50 and 75mM) reduced cell death caused by X+XO
for about 25% (Fig. 1b). At dose of 100mM this protective effect
of RSV disappeared. Longer (6h) pretreatment with RSV (50mM)
gave the same protection as was observed using a shorter (30min)
pretreatment.
The ability of RSV to decrease ROS levels in neuron-like PC6.3
cells, suggested us that RSV may have an influence on intracellular
antioxidants, such as SOD2 and TRX2. Therefore, we evaluated the
levels of these antioxidants and results showed that RSV (50mM;
24h) increases both mRNA and protein levels of mitochondrial
Fig. 1. 50–75mM RSV pretreatment decreases cell death and production of ROS
after oxidative stress. (a) Influence of RSV on ROS production. PC6.3 cells were pre-
treated with 50mM and 75mM RSV for 30min, and then stimulated with 100mM
xanthine (X) and 200mU/ml xanthine oxidase (XO) for 3h. ROS levels were deter-
mined using the dye DHE and FACSAria, and presented here as a quantification
of the data. X +XO treated cells are shown as black columns. 50mM and 75mM
RSV treatment decreased the production of ROS both alone and after exposure to
X+XO. Values are ±SEM, n=4. p<0.05 for XXO vs. XXO+RSV 50mM and for XXO
vs. XXO+RSV 75mM. (b) Effect of RSV on cell viability. PC6.3 cells were pretreated
with 50, 75 and 100mM RSV for 30min, and then stimulated with 50mM xanthine
(X) and 50mU/ml xanthine oxidase (XO) for 24h. X+XO treated cells are shown as
black columns. Cell viabilitywas determined using theMTT assay. 50mMand75mM
RSV pretreatment protected cells against death caused by X+XO, but the 100mM
RSV concentration did not show protective effect. Values are means± SEM, n=4–6.
p<0.05 for XXO vs. XXO+RSV 50mM, and p<0.01 for XXO vs. XXO+RSV 75mM.
antioxidants SOD2, and TRX2 (Fig. 2a–d). 75mM RSV gave essen-
tially the same results as 50mM. RSV also enhanced mRNA and
protein levels of anti-apoptotic protein XIAP (Fig. 2a–d). After a
longer treatment (72h), the effect of RSV on SOD2 and TRX2 was
even stronger, and the increasewasdetectable alreadywith smaller
concentrations (10 and 25mM) (Fig. 3).
Nextwe investigated theNFkB levels sincemany of the intracel-
lular antioxidants are known to be regulated by the NFkB system.
The NFkB Luciferase Reporter construct was used to study the acti-
vation level of NFkB in PC6.3 cells by stimulation with 50mM and
75mM RSV. After 24h, 50mM RSV had a small positive effect on
the activity of NFkB, but 75mM RSV did not (Fig. 4). After 48h,
both 50mM and 75mM RSV increased the activity of NFkB about
2.5 fold. The activation of NFkB may contribute to the increase in
antioxidants SOD2 and TRX2 mediated by RSV.
ROS levels are normally in balance with cellular antioxidants,
but increased ROS levels are found in neurodegenerative dis-
eases such as Huntington’s, Parkinson’s, and Alzheimer’s diseases
[4,10,21]. We observed that RSV reduces the basal levels of ROS
and significantly attenuates the increase in ROS caused by xanthine
and xanthine oxidase, and enhances the viability of the cells. Pre-
viously it has been reported that RSV can induce SOD2 in human
fibroblasts [22].We showhere that RSV elevated themitochondrial
antioxidants, SOD2 and TRX2, in PC6.3 cells both alone, and during
oxidative stress, when given as a pretreatment. The less prominent
effect of RSV in the oxidative stress condition compared to RSV
alone may be a consequence of the compensation mechanisms of
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Fig. 2. (a) Effect of RSV on protein levels of SOD2, TRX2 and XIAP. PC6.3 cells were pretreated with 50mM RSV for 30min, and then stimulated with X+XO for 24h. Protein
levels were determined using Western Blotting analysis. RSV treatment increased the protein levels of SOD2, TRX2 and XIAP both in control cells and in cells exposed to
X+XO. (b) Quantification of SOD2, TRX2 and XIAP proteins using ImageJ. Values are means± SEM, n=3. The influence of RSV on the protein levels of SOD2, TRX2 and XIAP
proteins is rising. (c) Influence of 75mM RSV treatment (24h) on mRNA levels of SOD2, XIAP and TRX2. mRNA levels were measured using PCR. RSV treatment increased the
mRNA amounts of SOD2, TRX2 and XIAP. (d) Effect of RSV together with 50mMxanthine (X) and 50mU/ml xanthine oxidase (XO). Cells were pretreated with RSV and 30min
after that, stimulated with X+XO for 24h. RSV (50mM; 24h) elevated the mRNA levels of SOD2, TRX2 and XIAP both alone and during exposure to oxidative stress by X+XO.
the cells. Maybe these mechanisms attempt to increase the levels
of antioxidants to reach the balance between oxidants and antiox-
idants within the cells, and that’s why the relative change caused
by RSV cannot be seen as clearly while oxidative stress prevails.
Anyhow, the beneficial effects of RSVmay be related to increases in
antioxidants, SOD2andTRX2. Inaddition to these,RSValsoelevated
both themRNAandprotein levelsof theanti-apoptoticproteinXIAP
in our study. At least regarding SOD2 and TRX2, the effect of RSV
seems to be time dependent, i.e. it will increase with the length of
Fig. 3. Longer RSV treatment gives further increase in the proteins levels of SOD2
and TRX2. PC6.3 cells were treated with 10, 25, 50 and 75mM RSV for 72h.
treatment. It remains to be studied which time and concentration
of RSV would be optimal for the impact as an antioxidant agent in
these cells.
Based on previous observations that XIAP increases SOD2 and
TRX2 in neuronal cells via NFkB activation [15], in present work
we evidenced that RSV enhances NFkB suggesting therefore that
increasedmitochondrial antioxidantsmay bemediated by NFkB. It
is known that RSV suppresses NFkB i.e. in carcinoma cells [3,18].
In neuronal cells there is not much evidence concerning RSV and
NFkB regulation, but it is known that RSV can have diverse effects
depending on cell types [23]. The same RSV concentration can be
protective in certain cell types and pernicious to others, and high
concentrations trigger apoptosis whereas low concentrations pro-
mote cell survival [12,13]. In this study, we observed only a small
increase in NFkB signaling after exposing cells to 50mM RSV for
24h. The 75mM concentration RSV did not enhance the activa-
tion of NFkB after 24h treatment at all. However, after 48h of
RSV treatment NFkB activity increased about 2.5 fold with both
concentrations. This would speak for the hypothesis that the lev-
els of antioxidants are more efficiently elevated after a longer
RVS treatment. Apart from NFkB, other signaling pathways are
probably involved in counteracting oxidative stress. Earlier it has
been shown that RSV is able to activate AMP-activated kinase
(AMPK), Silent InformationRegulator1 (SIRT-1), andPGC-1a [5,17].
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Fig. 4. After 24h, 50mMRSV had a small positive effect on the activity of NFkB, but
75mM RSV did not. After 48h, both 50mM and 75mM RSV increased the activity of
NFkB. Cellswere transfectedwithNFkB-Luciferase reporter plasmid and stimulated
with 50 and 75mM RSV for 24h and 48h. Co-transfection with Renilla expression
vector was used as control to assay transfection efficiency. Results are presented as
fold induction of Luciferase activity after of transfection. Values are means± SEM,
n=3. p<0.01 for RSV 50mM vs. control (C), and for RSV 75mM vs. control (C) after
48h of stimulation.
It remains to be studied whether some of these pathways are
influenced by RSV in PC6.3 cells. PGC-1a has previously been
linked to intracellular antioxidant proteins and the action of RSV
[17,24].
In this work, we demonstrate that RSV protects neuron-like
PC6.3-cells from cell death caused by oxidative stress, and RSV
reduced the generation of intracellular ROS. The precise timing
and optimal dose of RSV may vary between cell types. Treatment
of PC6.3 cells with 50–75mM RSV increased viability if cells, but
100mM concentration showed no significant effect. RSV is known
to cross the blood–brain barrier (BBB) [6], and to have beneficial
effects in acute brain insults and in some neurodegenerative disor-
ders. In contrast to neurons, others have reported death-inducing
effects of RSV i.e. in endothelial cells and in tumor cells including
glioma cells [14,23]. As shownhere, RSV at low concentrations pro-
motes cell viability while at high concentrations it may exert some
adverse effects that need to be taken into account. RSV is consid-
ered as a drug candidate for brain disorders, but the use of it will
need careful analysis of its kinetics, actions and pharmacological
and toxicological profiles.
Acknowledgements
This work is supported by Grants from the Sigrid Juselius Foun-
dation, the Finnish Parkinson Foundation and theWilhelm and Else
Stockmann Foundation.
References
[1] B.B. Aggarwal, A. Bhardwaj, R.S. Aggarwal, N.P. Seeram, S. Shishodia, Y. Takada,
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical
studies, Anticancer Res. 24 (5A) (2004) 2783–2840.
[2] T.S. Anekonda, Resveratrol – a boon for treating Alzheimer’s disease? Brain Res.
Rev. 52 (2) (2006) 316–326.
[3] S. Banerjee, C. Bueso-Ramos, B.B. Aggarwal, Suppression of 7,12-
dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats
by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix
metalloprotease 9, Cancer Res. 62 (17) (2002) 4945–4954.
[4] K.J. Barnham, C.L. Masters, A.I. Bush, Neurodegenerative diseases and oxidative
stress, Nat. Rev. Drug Discov. 3 (3) (2004) 205–214.
[5] J.A. Baur, K.J. Pearson, N.L. Price, H.A. Jamieson, C. Lerin, A. Kalra, V.V. Prabhu,
J.S. Allard, G. Lopez-Lluch, K. Lewis, P.J. Pistell, S. Poosala, K.G. Becker, O. Boss, D.
Gwinn,M.Wang, S. Ramaswamy, K.W. Fishbein, R.G. Spencer, E.G. Lakatta, D. Le
Couteur, R.J. Shaw, P. Navas, P. Puigserver, D.K. Ingram, R. de Cabo, D.A. Sinclair,
Resveratrol improves health and survival of mice on a high-calorie diet, Nature
444 (7117) (2006) 337–342.
[6] J.A. Baur,D.A. Sinclair, Therapeutic potential of resveratrol: the invivoevidence,
Nat. Rev. Drug Discov. 5 (6) (2006) 493–506.
[7] J. Blanchet, F. Longpre, G. Bureau, M. Morissette, T. DiPaolo, G. Bronchti, M.G.
Martinoli, Resveratrol, a red wine polyphenol, protects dopaminergic neurons
in MPTP-treated mice, Prog. Neuropsychopharmacol. Biol. Psychiatry 32 (5)
(2008) 1243–1250.
[8] J. Chao, M.S. Yu, Y.S. Ho, M. Wang, R.C. Chang, Dietary oxyresveratrol pre-
vents parkinsonian mimetic 6-hydroxydopamine neurotoxicity, Free Radic.
Biol. Med. 45 (7) (2008) 1019–1026.
[9] D. Della-Morte, K.R. Dave, R.A. DeFazio, Y.C. Bao, A.P. Raval, M.A. Perez-Pinzon,
Resveratrol pretreatment protects rat brain from cerebral ischemic damage
via a sirtuin 1-uncoupling protein 2 pathway, Neuroscience 159 (3) (2009)
993–1002.
[10] Y.E. Henrotin, P. Bruckner, J.P. Pujol, The role of reactive oxygen species in
homeostasis and degradation of cartilage, Osteoarthritis Cartilage 11 (10)
(2003) 747–755.
[11] A.L. Holme, S. Pervaiz, Resveratrol in cell fate decisions, J Bioenerg. Biomembr.
39 (1) (2007) 59–63.
[12] K. In, J. Park, H. Park, Resveratrol at high doses acts as an apoptotic inducer in
endothelial cells, Cancer Res. Treat. 38 (1) (2006) 48–53.
[13] M. Jang, L. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W. Beecher, H.H. Fong,
N.R. Farnsworth, A.D. Kinghorn, R.G. Mehta, R.C. Moon, J.M. Pezzuto, Cancer
chemopreventive activity of resveratrol, a natural product derived fromgrapes,
Science 275 (5297) (1997) 218–220.
[14] H Jiang, X. Shang, H. Wu, S.C. Gautam, S. Al-Holou, C. Li, J. Kuo, L. Zhang,
M. Chopp, Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in
human U251 glioma cells, J. Exp. Ther. Oncol. 8 (1) (2009) 25–33.
[15] M. Kairisalo, L. Korhonen, K. Blomgren, D. Lindholm, X-linked inhibitor of
apoptosis protein increases mitochondrial antioxidants through NF-kappaB
activation, Biochem. Biophys. Res. Commun. 364 (1) (2007) 138–144.
[16] J.K. Kundu, K.S. Chun, S.O. Kim, Y.J. Surh, Resveratrol inhibits phorbol ester-
induced cyclooxygenase-2 expression in mouse skin: MAPKs and AP-1 as
potential molecular targets, Biofactors 21 (1–4) (2004) 33–39.
[17] M. Lagouge, C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin,
N. Messadeq, J. Milne, P. Lambert, P. Elliott, B. Geny, M. Laakso, P. Puigserver,
J. Auwerx, Resveratrol improves mitochondrial function and protects against
metabolic disease by activating SIRT1 and PGC-1alpha, Cell 127 (6) (2006)
1109–1122.
[18] S.K. Manna, A. Mukhopadhyay, B.B. Aggarwal, Resveratrol suppresses TNF-
induced activation of nuclear transcription factors NF-kappa B, activator
protein-1, and apoptosis: potential role of reactive oxygen intermediates and
lipid peroxidation, J. Immunol. 164 (12) (2000) 6509–6519.
[19] MOkawara, H. Katsuki, E. Kurimoto, H. Shibata, T. Kume, A. Akaike, Resveratrol
protects dopaminergic neurons inmidbrain slice culture frommultiple insults,
Biochem. Pharmacol. 73 (4) (2007) 550–560.
[20] J.A. Parker, M. Arango, S. Abderrahmane, E. Lambert, C. Tourette, H. Catoire, C.
Neri, Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and
mammalian neurons, Nat. Genet. 37 (4) (2005) 349–350.
[21] A.C. Rego, C.R. Oliveira, Mitochondrial dysfunction and reactive oxygen species
in excitotoxicity and apoptosis: implications for the pathogenesis of neurode-
generative diseases, Neurochem. Res. 28 (10) (2003) 1563–1574.
[22] E.L. Robb,M.M. Page, B.E.Wiens, J.A. Stuart,Molecularmechanisms of oxidative
stress resistance induced by resveratrol: specific and progressive induction of
MnSOD, Biochem. Biophys. Res. Commun. 367 (2) (2008) 406–412.
[23] M. Shakibaei, K.B. Harikumar, B.B. Aggarwal, Resveratrol addiction: to die or
not to die, Mol. Nutr. Food Res. 53 (1) (2009) 115–128.
[24] J. St-Pierre, S. Drori, M. Uldry, J.M. Silvaggi, J. Rhee, S. Jager, C. Handschin, K.
Zheng, J. Lin, W. Yang, D.K. Simon, R. Bachoo, B.M. Spiegelman, Suppression of
reactive oxygen species and neurodegeneration by the PGC-1 transcriptional
coactivators, Cell 127 (2) (2006) 397–408.
[25] J. Wang, L. Ho, Z. Zhao, I. Seror, N. Humala, D.L. Dickstein, M. Thiyagarajan,
S.S. Percival, S.T. Talcott, G.M. Pasinetti, Moderate consumption of Cabernet
Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer’s
disease, FASEB J. 20 (13) (2006) 2313–2320.
